107 related articles for article (PubMed ID: 8406192)
1. Flow cytometry as a prognostic indicator in women with borderline epithelial ovarian tumors.
Harlow BL; Fuhr JE; McDonald TW; Schwartz SM; Beuerlein FJ; Weiss NS
Gynecol Oncol; 1993 Sep; 50(3):305-9. PubMed ID: 8406192
[TBL] [Abstract][Full Text] [Related]
2. The role of DNA flow cytometry in borderline malignant ovarian tumors.
Lai CH; Hsueh S; Chang TC; Tseng CJ; Huang KG; Chou HH; Chen SM
Cancer; 1996 Aug; 78(4):794-802. PubMed ID: 8756374
[TBL] [Abstract][Full Text] [Related]
3. Computerized image analysis and flow cytometric evaluation of ovarian borderline tumors: a study of 24 cases.
Esposito MJ; Fuchs A
Cytometry; 1994 Dec; 18(4):218-22. PubMed ID: 7895528
[TBL] [Abstract][Full Text] [Related]
4. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
Kimmig R; Wimberger P; Hillemanns P; Kapsner T; Caspari C; Hepp H
Gynecol Oncol; 2002 Jan; 84(1):21-31. PubMed ID: 11748971
[TBL] [Abstract][Full Text] [Related]
5. Epithelial ovarian tumors of borderline malignancy: long-term follow-up.
Casey AC; Bell DA; Lage JM; Fuller AF; Nikrui N; Rice LW
Gynecol Oncol; 1993 Sep; 50(3):316-22. PubMed ID: 8406194
[TBL] [Abstract][Full Text] [Related]
6. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of nuclear DNA quantification and cyclin A expression in epithelial ovarian carcinoma.
Yoon BS; Kim YT; Kim S; Lee CS; Kim JW; Kim JH; Kim SW; Cho NH
Eur J Obstet Gynecol Reprod Biol; 2008 Jan; 136(1):110-5. PubMed ID: 17157431
[TBL] [Abstract][Full Text] [Related]
8. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic factors in neuroblastoma. Usefulness of DNA analysis using flow cytometry on paraffin-embedded material].
Massara FM; Tonello M; Forni M; Fruttero A; Lantermo R; Pugno F; Cordero di Montezemolo L; Ruà S
Pediatr Med Chir; 1996; 18(2):141-8. PubMed ID: 8767575
[TBL] [Abstract][Full Text] [Related]
10. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
11. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers.
Henriksen R; Strang P; Backstrom T; Wilander E; Tribukait B; Oberg K
Anticancer Res; 1994; 14(2B):603-8. PubMed ID: 8010717
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
13. Influence of cellular DNA content on survival in advanced ovarian cancer.
Friedlander ML; Hedley DW; Taylor IW; Russell P; Coates AS; Tattersall MH
Cancer Res; 1984 Jan; 44(1):397-400. PubMed ID: 6690054
[TBL] [Abstract][Full Text] [Related]
14. [Ovarian epithelial tumors of borderline malignancy].
Katoh K; Izumi R
Rinsho Byori; 1992 Feb; 40(2):119-31. PubMed ID: 1583784
[TBL] [Abstract][Full Text] [Related]
15. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
[TBL] [Abstract][Full Text] [Related]
16. Mucinous borderline and malignant tumors of the ovary. A clinicopathologic and DNA ploidy study of 92 cases.
Guerrieri C; Högberg T; Wingren S; Fristedt S; Simonsen E; Boeryd B
Cancer; 1994 Oct; 74(8):2329-40. PubMed ID: 7922984
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of morphometric and DNA flow cytometric variables as independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study.
Veerman MM; van der Wurff AA; van de Water M; Kruitwagen RF; Feijen HW; Vos MC
Int J Gynecol Pathol; 2009 Sep; 28(5):432-41. PubMed ID: 19696612
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of DNA ploidy status in patients with rectal cancer.
Berczi C; Bocsi J; Bartha I; Math J; Balazs G
Anticancer Res; 2002; 22(6B):3737-41. PubMed ID: 12552986
[TBL] [Abstract][Full Text] [Related]
19. Proliferating cell nuclear antigen (PCNA) and Ki-67 in epithelial ovarian tumours: correlation with DNA flow cytometric analysis.
Karaburun S; Karaveli S; Peştereli HE; Simsek T; Sargin CF
Adv Clin Path; 2001 Jan; 5(1-2):3-9. PubMed ID: 11753828
[TBL] [Abstract][Full Text] [Related]
20. Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors.
Fu YS; Ro J; Reagan JW; Hall TL; Berek J
Obstet Gynecol; 1986 Apr; 67(4):478-82. PubMed ID: 3960418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
